Recherche dans les collections de brevets nationales et internationales
Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (AU2016250100) Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique
CLAIMS
We Claim:
1.           A method for at least one of characterizing, diagnosing, and treating a cutaneous condition in at least a subject, the method comprising:
* at a sample handling network, processing nucleic acid content of each of an aggregate set of samples, from a population of subjects, with a fragmentation operation, a multiplexed amplification operation using a set of primers, a sequencing analysis operation, and an alignment operation;
* at a computing system in communication with the sample handling network, generating a microbiome composition dataset and a microbiome functional diversity dataset upon processing of the aggregate set of samples;
* at the computing system, receiving a supplementary dataset informative of the cutaneous condition within the population of subjects,;
* at the computing system, transforming the supplementary dataset and features extracted from the microbiome composition dataset and the microbiome functional diversity dataset into a characterization model of the cutaneous condition;
* generating a therapy model, associated with the characterization model, configured to improve a state of the cutaneous condition; and
* at an output device associated with the subject, promoting a therapy to the subject, upon characterizing the subject with the cutaneous condition according to the characterization model and the therapy model.
2.           The method of Claim 1, wherein generating the characterization model comprises performing a statistical analysis to assess a set of microbiome composition features and microbiome functional features having variations across a first subset of the population of subjects exhibiting the cutaneous condition and a second subset of the population of subjects not exhibiting the cutaneous condition.
3.           The method of Claim 2, wherein generating the characterization model of the cutaneous condition comprises generating a characterization that is diagnostic of a skin condition.
4.           The method of Claim 3, wherein generating the characterization model of the cutaneous condition comprises generating the characterization of at least one of: aene and dermatomyositis.
5.           The method of Claim 4, wherein generating the characterization that is diagnostic of acne comprises generating the characterization upon processing the aggregate set of samples and determining presence of features derived from a set of taxa including: Phascolarctobacterium (genus).
6.           The method of Claim 5, wherein generating the characterization further comprises determining presence of features derived from a set of functions.
7.           The method of Claim 6, wherein generating the set of functions includes a lepB TPP signal peptidase KEGG orthology-derived feature.
8.           The method of Claim 4, wherein generating the characterization that is diagnostic of dermatomyositis comprises generating the characterization upon processing the aggregate set of samples and determining presence of features derived from a set of taxa including at least one of: Faecalibacterium (genus), Ruminococcaceae (family), and Bacteroidia (class).
9.           The method of Claim 8, wherein generating the characterization further comprises determining presence of features derived from a set of functions.
10.         The method of Claim 9, wherein generating the set of functions includes a first feature related to energy metabolism, a second feature related to immune system, and a third feature related to D-Alanine metabolism.
11.         The method of Claim 2, wherein generating the characterization model of the cutaneous condition comprises generating a characterization that is diagnostic of at least one of: a hair condition, a nail condition, and a cutaneous gland condition.
12.         The method of Claim 2, wherein generating the characterization model comprises: * extracting candidate features associated with a set of functional aspects of microbiome components indicated in the microbiome composition dataset to generate the microbiome functional diversity dataset; and
- characterizing the cutaneous condition in association with a subset of the set of functional aspects, the subset derived from at least one of clusters of orthologous groups of proteins features, genomic functional features, chemical functional features, and systemic functional features.
13.         A method for characterizing a cutaneous condition in a subject, the method comprising:
* upon processing an aggregate set of samples from a population of subjects, generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects, the microbiome functional diversity dataset indicative of systemic functions present in the microbiome components of the aggregate set of samples;
* at the computing system, transforming features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset into a characterization model of the cutaneous condition, wherein the characterization model is diagnostic of at least one of a skin condition; and
* generating a therapy model, associated with the characterization model, configured to improve a state of the cutaneous condition.
14.         The method of Claim 13, wherein generating the characterization model comprises analyzing a set of features form the microbiome composition dataset with a statistical analysis, wherein the set of features includes features associated with interactions between different taxonomic groups represented in the microbiome composition dataset and phylogenetic distance between taxonomic groups represented in the microbiome composition dataset.
15.         The method of Claim 13, wherein generating the characterization comprises performing a statistical analysis with at least one of a Kolmogorov-Smirnov test and a Welch's t-test to assess a set of microbiome composition features and microbiome functional features having variations across a first subset of the population of subjects exhibiting the cutaneous condition and a second subset of the population of subjects not exhibiting the cutaneous condition.
16.         The method of Claim 13, wherein generating the characterization model of the skin condition comprises generating the characterization of at least one of: aene and dermatomyositis.
17.         The method of Claim 16, wherein generating the characterization that is diagnostic of acne comprises generating the characterization upon processing the aggregate set of samples and determining presence of features derived from 1) a set of taxa including: Phascolarctobacterium (genus) and 2) a set of functions including a first functional feature related to lepB TPP signal peptidase.
18.         The method of Claim 16, wherein generating the characterization that is diagnostic of dermatomyositis comprises generating the characterization upon processing the aggregate set of samples and determining presence of features derived from 1) a set of taxa including at least one of: Faecalibacterium (genus), Ruminococcaceae (family), and Bacteroidia (class) and 2) a set of functions including a first functional feature related to energy metabolism, a second feature related to immune system, and a third feature related to D-Alanine metabolism.
19.         The method of Claim 13, further including diagnosing a subject with the cutaneous condition upon processing a sample from the subject according to the characterization model; and at an output device associated with the subject, promoting a therapy to the subject based upon the therapy model.
20.         The method of Claim 19, wherein promoting the therapy comprises promoting at least one of a probiotic therapy and a prebiotic therapy to the subject, the therapy including a consumable component adjusting microbiome composition of the subject to improve the state of the cutaneous condition.
21.         The method of Claim 19, wherein promoting the therapy comprises promoting a microbiome composition modifying therapy to the subject in order to improve a state of the cutaneous condition.